RT info:eu-repo/semantics/article
T1 Fecal Gluten Peptides Reveal Limitations of Serological Tests and Food Questionnaires for Monitoring Gluten-Free Diet in Celiac Disease Patients
A1 Comino, Isabel
A1 Fernández Bañares, Fernando
A1 Esteve, María
A1 Ortigosa, Luís
A1 Castillejo, Gemma
A1 Fambuena, Blanca
A1 Ribes-Koninckx, Carmen
A1 Sierra, Carlos
A1 Rodríguez Herrera, Alfonso
A1 Salazar, José Carlos
A1 Caunedo, Ángel
A1 Marugán de Miguelsanz, José Manuel
A1 Garrote Adrados, José Antonio
A1 Vivas, Santiago
A1 lo Iacono, Oreste
A1 Nuñez, Alejandro
A1 Vaquero, Luis
A1 Vegas Álvarez, Ana María
A1 Crespo Valderrabano, Laura
A1 Fernández Salazar, Luis Ignacio
A1 Jiménez García, Victoria Alejandra
A1 Montes Cano, Marco Antonio
A1 Espín, Beatriz
A1 Galera, Ana
A1 Valverde, Justo
A1 Girón, Francisco José
A1 Bolonio, Miguel
A1 Millán, Antonio
A1 Martínez Cerezo, Francesc
A1 Guajardo, César
A1 Alberto, José Ramón
A1 Rosinach, Mercé
A1 Segura, Verónica
A1 León, Francisco
A1 Marinich, Jorge
A1 Muñoz Suano, Alba
A1 Romero Gómez, Manuel
A1 Cebolla, Ángel
A1 Sousa, Carolina
A1 Arranz Sanz, Eduardo
K1 Gluten
K1 3206 Ciencias de la Nutrición
AB Objectives: Treatment for celiac disease (CD) is a lifelong strict gluten-free diet (GFD). Patients should be followed-up with dietary interviews and serology as CD markers to ensure adherence to the diet. However, none of these methods offer an accurate measure of dietary compliance. Our aim was to evaluate the measurement of gluten immunogenic peptides (GIP) in stools as a marker of GFD adherence in CD patients and compare it with traditional methods of GFD monitoring.Methods: We performed a prospective, nonrandomized, multicenter study including 188 CD patients on GFD and 84 healthy controls. Subjects were given a dietary questionnaire and fecal GIP quantified by enzyme-linked immunosorbent assay (ELISA). Serological anti-tissue transglutaminase (anti-tTG) IgA and anti-deamidated gliadin peptide (anti-DGP) IgA antibodies were measured simultaneously.Results: Of the 188 celiac patients, 56 (29.8%) had detectable GIP levels in stools. There was significant association between age and GIP in stools that revealed increasing dietary transgressions with advancing age (39.2% in subjects ≥13 years old) and with gender in certain age groups (60% in men ≥13 years old). No association was found between fecal GIP and dietary questionnaire or anti-tTG antibodies. However, association was detected between GIP and anti-DGP antibodies, although 46 of the 53 GIP stool-positive patients were negative for anti-DGP.Conclusions:  Detection of gluten peptides in stools reveals limitations of traditional methods for monitoring GFD in celiac patients. The GIP ELISA enables direct and quantitative assessment of gluten exposure early after ingestion and could aid in the diagnosis and clinical management of nonresponsive CD and refractory CD. Trial registration number NCT02711397
PB Lippincott, Williams & Wilkins
SN 0002-9270
YR 2016
FD 2016
LK http://uvadoc.uva.es/handle/10324/41114
UL http://uvadoc.uva.es/handle/10324/41114
LA eng
NO The American Journal of Gastroenterology, 2016,111:1456–1465
NO Producción Científica
DS UVaDOC
RD 28-abr-2024